NOW FOR SOMETHING COMPLETELY DIFFERENT - CANNABIS SUGARS
Natural low calorie plant sugar merges with cannabis
"These new sugar-cannabis molecules can be easily mixed into tea, coffee or edibles which are sweet to the taste, as opposed to "tasting like ass", as some people say. And these molecules could very well work better then already effective cannabinoids THC & CBD."
There is little chance you'll get fat by consuming this new type of cannabis.
A new elite cannabis based medicine company, Vitality Biopharma recently published data on the discovery of marijuana Cannabinoid glycosides. Simply put, the Vitality scientists have found a way to attach a natural sugar onto cannabinoid molecules (such as CBD) using an enzyme from a Stevia plant. Vitality boasts a management and scientific team with a long history of success in the pharmaceutical industry, in both discovery and funding. It would seem that if anything can be made of this branch of research, the odds favor this mature group.
In this process, a cannabinoid glycoside is formed when a simple sugar with bonds with a cannabinoid, such as THC, CBD, (OH replacement), to produce a compound with new biochemical properties. Scientists are excited about the discovery of cannabis sugars is exciting because many popular drugs (and poisons) are composed of glycosides extracts from other plant species.
The parent molecule in many of Vitality's discovery drugs is CBD (cannabidiol), whose role as a neuro-protector and regenerator is well established. CBD’s was shown in preclinical models to be critical to brain repair in multiple sclerosis. Novel analogues (similar-substances) produced via "natural' enzymatic reactions with CBD have a good chance (predicted by models) to afford enhanced or unique medicinal properties as compared to CBD and THC.
WHAT IS A GLYCOSIDE?
A simple molecule attached to another molecule (above). The group on the left with a lot of OH is a sugar. The ring is the parent molecule. Together they are called a glycoside.
Vitality Biopharma is dedicated to the development of cannabinoid prodrugs. What is a prodrug?
A prodrug is metabolized or converted by the body after administration into a pharmacologically active drug. Vitality Biopharma's put the sugar onto the cannabis - glycosylation through enzymatic biosynthesis effectively created this new class of cannabinoid glycosides called “cannabosides.”
“Anti Inflammatory action of CBD - CBD modulates the CB2 receptors, which represent a braking system for… the resolution of inflammation and many of its symptoms.”
Vitality is now working on clinical application of its novel repertoire of drugs for neurological and inflammatory disorders. They want to show beyond reasonable doubt that cannabinoid glycosides demonstrate improved medicinal properties. Critical to everything is the discovery of a multifunctional plant enzyme in the Stevia plant, that is used to produce cannabosides. Stevia is an extremely sweet (but low calorie) natural substance found in the plant species Stevia rebaudiana. Research findings here: Cannabinoid glycosides: In vitro production of a new class of cannabinoids with improved physicochemical properties.
These cannabosides are expected to have a low-cost, low-risk drug profile. Clinical trials will prove this out. Their pipeline (assortment of drugs) includes more than twenty cannabis prodrugs which are modifications non-psychoactive CBD, CBDV and THC types. Of special interest is the treatment of anti inflammatory conditions that affect the gastrointestinal tract and central nervous system, including Crohn's and opiate induced abdominal pain.
Focal Areas of Preclinical and Clinical Study of Cannabis Glycosides
Novel Cannabidiol Clinical Trials
Epilepsy / Seizures
Psychosis / Schizophrenia
Muscle spasticity MS
Inflammatory Bowel Diseases
Prodrugs have a long history. Because a reference drug can already be independently verified for efficacy and safety, the prodrug can be rapidly approved through the demonstration of bioequivalence. Also novel prodrugs can be marketed more quickly due to its ability to eliminate negative side effects. A classic example of a prodrug is Aspirin or acetylsalicylic acid made by Bayer more than one hundred years ago. Now prodrugs annual sales in America are in excess of $1 billion USD.
“Cannabidiol… represents a rare, if not unique, compound that is affords neuroprotection by the combination of different types of properties e.g., anti-glutamatergic effects, anti-inflammatory action, and antioxidant effects” (Iuvone et. al., 2009)."
ADVANTAGES OF GLYCOSIDE PRODRUGS
These novel oral prodrugs could be more convenient and acceptable to patients and physicians than injectables.
Novel cannabis prodrugs might be site specific, allowing for targeted treatment of disorders like inflammatory bowel disease, while avoiding the build up of high concentrations of THC. ie.e medicate without getting high.
Better dosing could result because novel cannabis prodrugs can avoid degradation by acids in the stomach.
Cannabis prodrugs might have fewer side effects as compared to THC.
Oral water soluble glycoside prodrugs are less harsh as compared to other preparations, such as tinctures with pure alcohol, which burns the lining of the mouth with frequent use.
Glycoside sweet tasting prodrugs are more palatable, preferred by the vast majority of the population, in comparison to bitter and repugnant forms.
FACTS AND FIGURES - 2016
Synthetic cannabinoid drug sales are about $150 million
Legal medical marijuana sales estimated at $4.5 billion
Total recreational and medical marijuana market estimated at $50 billion
Total projected marijuana market in 2025, $100 billion plus, plus
CLINICAL DEVELOPMENT - V SERIES OF CANNA-DRUGS
VB100 Inflammatory Bowel Disease Phase 1/2 Studies 2017
VB210 Neuropathic Pain, Irritable Bowel Syndrome, Fibromyalgia, Muscle Spasticity
in MS Phase 1/2 Studies 2017
Cannaboside Formulations Epilepsy, Schizophrenia, Huntington’s, Guillain-Barré Preclinical
Pursuing low-risk approvals clinical uses of cannabinoids, with exploratory use in large market indications
HELP FROM OTHER RESEARCHERS
Cannabis Drug discovery companies may benefit from ongoing clinical studies initiated and paid for by independent clinical investigators in epilepsy, neuropathic pain, multiple sclerosis, inflammatory bowel disease, schizophrenia, and Huntington’s disease.
Promising studies, like these are being repeated in clinical setting across the world.
Given the minimal toxicity of cannabinoids found in hemp and cannabis, and in light of the non-effectiveness of pharmaceutical preparations, shouldn't every MS sufferer should investigate the use of cannabis based medicines, not only in the treatment of MS symptoms, but the disease itself.
OUR READERSHIP STEREOTYPED - FEMALE AND EDUCATED
420EvaluationsOnline: Your support will allow our medical team to keep putting out articles on important topics. It takes a lot of time to dig into the medical annals and sort out the nitty gritty on technical topics, and present findings in a form that our readers can understand. Interestingly, our readership as reported by Amazon is 70% women and nearly all have gone to college. Further 25 % or readers report that they have a graduate school education.
So, if you need a medical marijuana 420 evaluations, growers permits, cannabis ID cards online, you can help yourself and this cause by getting your documents here. Infact, our streamlined process is among the most affordable anywhere. Services complies with the California Board of Medicine guidelines for Telehealth services.
Clients simply fill out personal info and specify your conditions and symptoms here. A licensed medical doctor reviews your file the same day. Patients only pay once they are approved. Our documents are used at cannabis dispensaries, clinics, cooperatives, delivery services throughout California and Nevada.
SECRETS OF THE UNIVERSE - HOW TO MAKE A SUGAR
The beauty of plant derived medicines is that life forms are able to metabolize them, while synthetic and genetic modifications result in chemical forms that cannot be metabolized and or are toxic to the organisms, simply because they are not adapted to, don't know what to do with these "alien" molecules.
Cannabinoid glycosides: In vitro production of a new class of WATER SOLUBLE COMPOUNDS OF CLINICAL INTEREST
The cannabinoid signaling system has recently garnered attention as a therapeutic target for numerous indications, and cannabinoids are now being pursued as new treatment options in diverse medical fields such as neurology, gastroenterology, pain management, and oncology. Cannabinoids are extremely hydrophobic and relatively unstable compounds, and as a result, formulation and delivery options are severely limited. Enzymatic glycosylation is a strategy to alter the physicochemical properties of small molecules, often improving their stability and aqueous
The scientific manuscript is titled, "Cannabinoid glycosides: In vitro production of a new class of cannabinoids with improved physicochemical properties," which details the scientific pathway undertaken by the Company's research and development team towards the discovery of a multifunctional plant enzyme from Stevia rebaudiana
Novel cannabinoid glycoside compositions of matter have reliably lead to dramatic improvements in drug solubility and stability, as evidenced below. Patents are pending for more than 20 novel cannabinoid glycoside prodrugs (including prodrug versions of of CBD, THC, CBDV, and more).
Recent research into improving the taste of stevia compounds led to the finding that the process could act equally well on a wide variety of molecules, especially natural products, including cannabinoids, and that it could act on them in ways that could dramatically improve their drug properties, including modifications to their solubility, stability, and bioavailability.
This work has enabled production of proprietary prodrug versions of each of the major cannabinoids that are being tested by the medical community today for treatment of a wide variety of disorders, including epilepsy, inflammatory bowel disease, and multiple sclerosis. The Company's work has focused primarily on cannabidiol, which is not psychoactive.
Cannabinoid Glycosides - PROSPECTUS
Unlocking the power of cannabinoids to treat serious neurological and inflammatory disorders
The scientific manuscript is titled, "Cannabinoid glycosides: In vitro production of a new class of cannabinoids with improved physicochemical properties," which details the scientific pathway undertaken by the Company's research and development team towards the discovery of a multifunctional plant enzyme from Stevia rebaudiana, as well as an ability to produce a diverse class of cannabinoid compounds known as cannabinoid glycosides.